Xembify not checked
Grifols Therapeutics LLC · IGSC 20%
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (IGSC 20%)”In the company’s words, NCT07540221 on ClinicalTrials.gov
- Tested for
- CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
- Main trialPhase 3
- “The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein once every 3 weeks in people with CIDP. Participants with CIDP will first have up to 28 days of screening to make sure they can join the study. Those who qualify will then start a 19-week treatment period with Gamunex-C. During this period, they will receive Gamunex-C through a vein once every 3 weeks, for a total of 7 doses. Approximately, one week after their last Gamunex-C dose, they will…”In the company’s words, NCT07540221 on ClinicalTrials.gov
- Other names
- IGSC 20%
Other drugs for CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
- NipocalimabJohnson & Johnson (Janssen) · Phase 2/3
- RiliprubartSanofi · Phase 3
- Empasiprubartargenx · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- Gamunex-CGrifols Therapeutics LLC · Phase 3
- HYQVIATakeda · Phase 3
Coming up2
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Aug 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2027 | A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | |
| Phase 3Recruiting | Aug 2029 | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma | |
| Phase 4Completed | 18 Jul 2022 | A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026